Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Monoamine oxidase B (MAO-B) metabolizes monoamines such as dopamine regarding neural transmission and controls its level in the mammalian's brain. When MAO-B metabolizes dopamine abnormally, normal neurotransmission does not occur, and central nervous system disorders such as Parkinson's disease may develop. Although several MAO inhibitors have been developed, most of them have no selectivity between monoamine oxidase A (MAO-A) and MAO-B, or they work irreversibly against the enzyme. This report describes the first case of screening of -arylated heliamine derivatives to develop novel MAO-B selective inhibitors that can be synthesized concisely by microwave-assisted Pd nanoparticle-catalyzed Buchwald-Hartwig amination. We discovered that the derivatives , , and display inhibitory activity against MAO-B with IC values of 1.55, 13.5, and 5.08 μM, respectively.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575162 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.2c00228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of C-3 nitrothiophene substituted thiochromone derivatives as potent and selective human monoamine oxidase B (hMAO-B) inhibitors for the treatment of atherosclerosis.
Bioorg Chem
August 2025
Key Lab of Protein Structure and Function of Universities in Hunan Province, University of South China, Hengyang, Hunan 421001, China; School of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan 421001, China. Electronic address:
Inhibition of human monoamine oxidase B (hMAO-B) to prevent both oxidative stress and lipid metabolism disorders, which are high-risk factors for pathogenesis of atherosclerosis, is a potential strategy for the treatment of atherosclerosis. In this study, we have explored a series of C-3 nitrothiophene substituted thiochromone analogues that showed good to excellent potency against hMAO-B. The strategy of introduction the nitro-group into thiophene linker, which contributes pivotal interactions with Cys172, significantly improved the potency and selectivity of these compounds.
View Article and Find Full Text PDFQuantification of monoamine oxidase B expression with C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer's disease.
Eur J Nucl Med Mol Imaging
September 2025
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Purpose: Astrocyte reactivation can be assessed using positron emission tomography (PET) ligands targeting monoamine oxidase B (MAO-B). C-SL25.1188 binds reversibly to MAO-B, allowing precise density measurements, but requires invasive arterial sampling.
View Article and Find Full Text PDFAntidepressants and Lung Toxicity: A Narrative Review.
Cureus
August 2025
Pulmonary and Critical Care Medicine, HCA Houston Healthcare Kingwood/University of Houston, Kingwood, USA.
Pulmonary toxicity is a serious yet frequently under-recognized complication of antidepressant therapy. With the continued rise in prescriptions, awareness of potential respiratory adverse effects is crucial. This review outlines documented cases of lung injury linked to various antidepressant classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, serotonin modulators, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
View Article and Find Full Text PDFPrecision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders.
Protein Pept Lett
September 2025
Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, 560111, India.
Introduction: Neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS are characterized by progressive neuronal dysfunction with limited therapeutic options. Recent advances in molecular biology and drug development have highlighted the therapeutic promise of precision enzyme targeting, offering novel strategies for disease modulation and symptom management.
Methods: A comprehensive literature review spanning recent/current was conducted using PubMed, Scopus, and ScienceDirect.
The interaction of antirenalase antibodies with full-length recombinant human renalases RNLS1 and RNLS2, as well as fragments of these proteins encoded by alternative exons 9 and 10 and expressed as fusion proteins with dihydrofolate reductase (DHFR) in Escherichia coli cells has been investigated. In this study we used custom made polyclonal antibodies to the full-length recombinant RNLS1 (amino acid residues (aa) 1-342), created at our request, as well as commercially available monoclonal antibodies to the renalase fragment (aa - 18-342), specific for the RNLS1 isoform and its C-terminal sequence encoded by exon 9. According to Western blot analysis, the antibodies interacted not only with recombinant RNLS1 and RNLS2 preparations, but also with fusion proteins containing C-terminal sequences specific for these isoforms (DHFR-RNLS-9ex and DHFR-RNLS-10ex).
View Article and Find Full Text PDF